BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27986437)

  • 1. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
    Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
    Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favourable response to rituximab by an ocular adnexal primary lymphoma.
    Luque Valentin-Fernandez ML; Alvarez Rodríguez F; Rodríguez Jiménez I
    Arch Soc Esp Oftalmol; 2016 Nov; 91(11):539-542. PubMed ID: 27125186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
    Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
    Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
    Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
    Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
    [No Abstract]   [Full Text] [Related]  

  • 5. Conjunctival and orbital lymphoma.
    Shinder R
    Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary conjunctival follicular lymphoma mimicking chronic conjunctivitis.
    Labrador Velandia S; García Lagarto E; Saornil MA; García Álvarez C; Cuello R; Diezhandino P
    Arch Soc Esp Oftalmol; 2016 Feb; 91(2):86-9. PubMed ID: 26560164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intralesional rituximab in ocular adnexal lymphoma].
    Crespo Robledo P; Vázquez Castillo MJ
    Farm Hosp; 2014 Jul; 38(4):386-7. PubMed ID: 25137174
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
    Celiker H; Toker E; Kaygusuz Atagunduz I
    Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma.
    Peinert S; Kamel S; Seymour JF; Prince HM
    Leuk Lymphoma; 2009 Feb; 50(2):303-5. PubMed ID: 19197721
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
    Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
    Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.
    Ferreri AJM; Sassone M; Miserocchi E; Govi S; Cecchetti C; Corti ME; Mappa S; Arcaini L; Zaja F; Todeschini G; Mannina D; Calimeri T; Perrone S; Ponzoni M; Modorati G
    Blood Adv; 2020 Mar; 4(6):1013-1019. PubMed ID: 32182364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Cencini E; Puccini B; Rigacci L; Fabbri A; Kovalchuk S; Mannelli L; Benelli G; Carfagno T; Simontacchi G; Bocchia M; Bosi A
    Leuk Lymphoma; 2018 Jun; 59(6):1420-1426. PubMed ID: 28994343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma.
    Demirci H; Kauh CY; Rajaii F; Elner VM
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S70-S71. PubMed ID: 26950471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma].
    Yang JP; Pang X; Zhang K; Wang LL; Zhu Y
    Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):839-845. PubMed ID: 33152842
    [No Abstract]   [Full Text] [Related]  

  • 15. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
    J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.
    Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
    Am J Hematol; 2016 Jun; 91(6):E305-7. PubMed ID: 26950187
    [No Abstract]   [Full Text] [Related]  

  • 17. Bilateral conjunctival follicular lymphoma in a child.
    Wall PB; Traboulsi EI; Hsi ED; Singh AD
    J AAPOS; 2015 Apr; 19(2):183-5. PubMed ID: 25824110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case Report of Conjunctival Extranodal Marginal Zone Lymphoma Treated with Intralesional Rituximab Injection Therapy.
    Yazicioglu T; Oklar M; Kocabas S; Karadag E; Elibol V; Tezcan ME
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1329-1333. PubMed ID: 36084297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in follicular lymphoma.
    Flowers CR; Leonard JP; Fowler NH
    Blood; 2020 Jun; 135(24):2133-2136. PubMed ID: 32236519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
    Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
    Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.